secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071385
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M
--------------------------------------------------------------------

- Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.
- Cash, equivalents and securities $164.8M; runway into Q2 2027.
- ACR-368 Phase 2b: 35% cORR, 80% DCR in OncoSignature+ patients; 50% cORR in relapsed subset.
- ACR-2316 Phase 1: DL4 enrolling; ~25% tumor shrinkage at DL3 below projected RP2D.
- Appointed Mansoor Raza Mirza as CMO; promoted Adam Levy to CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/0000950170-25-071385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/acrv-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer